Department of Clinical Oncology, Queen Elizabeth Hospital, Room 1305, 13/F, Block R, 30 Gascoigne Road, Kowloon, Hong Kong.
Expert Opin Ther Targets. 2012 Aug;16(8):747-59. doi: 10.1517/14728222.2012.696102. Epub 2012 Jun 13.
The results of cancer-associated miRNA research have yielded surprising insights into the pathogenesis of a range of different cancers. Many of the dysregulated miRNAs are involved in the regulation of genes that are essential for carcinogenesis.
This review discusses the latest discovery of miRNAs acting as oncogenes and tumor suppressor genes, as well as the potential applications of miRNA regulations in cancer therapy. Several translational studies have demonstrated the feasibility of targeting oncogenic miRNAs and restoring tumor-suppressive miRNAs for cancer therapy using in vivo model systems.
miRNAs are extensive regulators of cancer progression. With increasing understanding of the miRNA target genes and the cellular behaviors influenced by them, modulating the miRNA activities may provide exciting opportunities for cancer therapy. Despite the hurdles incurred in acquiring effective systemic drug delivery systems, in vivo delivery of miRNAs for therapeutic purposes in preclinical animal models is rapidly developing. Accumulating evidences indicate that using miRNA expression alterations to influence molecular pathways has the potential of being translated into clinical applications.
癌症相关 miRNA 研究的结果出人意料地揭示了多种不同癌症的发病机制。许多失调的 miRNA 参与了对致癌基因的调控。
本文讨论了 miRNA 作为癌基因和肿瘤抑制基因的最新发现,以及 miRNA 调控在癌症治疗中的潜在应用。几项转化研究表明,使用体内模型系统靶向致癌 miRNA 并恢复肿瘤抑制 miRNA 用于癌症治疗是可行的。
miRNA 是癌症进展的广泛调节因子。随着对 miRNA 靶基因及其影响的细胞行为的深入了解,调节 miRNA 活性可能为癌症治疗提供令人兴奋的机会。尽管在获得有效的全身药物递送系统方面存在障碍,但在临床前动物模型中为治疗目的输送 miRNA 的体内递送正在迅速发展。越来越多的证据表明,利用 miRNA 表达的改变来影响分子途径有可能转化为临床应用。